Filing Details

Accession Number:
0001179110-12-012003
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-30 21:48:54
Reporting Period:
2012-07-26
Filing Date:
2012-07-30
Accepted Time:
2012-07-30 21:48:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
896264 Usana Health Sciences Inc USNA Medicinal Chemicals & Botanical Products (2833) 870500306
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1441748 Deborah Woo 3838 West Parkway Blvd.
Salt Lake City UT 84120
President Of Asia Pacific No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-26 201 $40.59 201 No 4 M Direct
Common Stock Disposition 2012-07-26 201 $43.04 0 No 4 S Direct
Common Stock Acquisiton 2012-07-26 3,795 $26.06 3,795 No 4 M Direct
Common Stock Disposition 2012-07-26 3,795 $43.04 0 No 4 S Direct
Common Stock Acquisiton 2012-07-27 3,679 $26.06 3,679 No 4 M Direct
Common Stock Disposition 2012-07-27 1,575 $44.45 2,104 No 4 S Direct
Common Stock Disposition 2012-07-27 2,104 $45.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-26 6,000 $0.00 6,000 $40.59
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-26 10,000 $0.00 10,000 $26.06
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-27 9,000 $0.00 9,000 $26.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2008-04-19 2012-10-19 No 4 M Direct
38,000 2009-07-21 2014-01-21 No 4 M Direct
29,000 2009-07-21 2014-01-21 No 4 M Direct
Footnotes
  1. The shares acquired resulted from the reporting person's settlement of the stock-settled stock appreciation rights desclosed in Table II.